Myasthenia Gravis Treatment Market Report 2025

The myasthenia gravis treatment market size has grown strongly in recent years. It will grow from $1.55 billion in 2024 to $1.66 billion in 2025 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to cholinesterase inhibitors, thymectomy procedures, immunosuppressive therapies, the emergence of plasma exchange, and patient advocacy.

The myasthenia gravis treatment market size is expected to see strong growth in the next few years. It will grow to $2.26 billion in 2029 at a compound annual growth rate (CAGR) of 8%. The growth in the forecast period can be attributed to biologics and monoclonal antibodies, genetic and precision medicine, emerging immune modulators, neuroprotective strategies, and biosimilar medications. Major trends in the forecast period include digital therapeutics, collaborative research initiatives, patient-centric approaches, real-world evidence utilization, and long-term safety monitoring.

The rise in the incidence of myasthenia gravis is anticipated to drive the growth of the myasthenia gravis treatment market in the future. Myasthenia gravis is an autoimmune neuromuscular disorder characterized by fatigue and weakness in the skeletal muscles. Treatment for myasthenia gravis involves delivering healthcare services and care to help patients manage the condition. Consequently, the increasing prevalence of myasthenia gravis is enhancing sales in the treatment market. For instance, data published by the National Organization for Rare Disorders in January 2022 indicated that autoimmune myasthenia gravis has an estimated prevalence of 14-40 per 100,000 individuals in the United States. Additionally, a report from the American Journal of Managed Care in April 2024, based on an average of 1,800 annual diagnoses, estimated an incidence rate of 4.32 cases per 100,000 individuals and a rate of 2.46 cases per 100,000 person-years. Thus, the growing prevalence of myasthenia gravis is fueling the expansion of the myasthenia gravis treatment market.

Rising healthcare spending is fueling growth in the myasthenia gravis treatment market. Healthcare spending represents the total financial resources allocated to the healthcare sector within a given region, country, or organization. Such spending is essential for treating myasthenia gravis (MG), an autoimmune neuromuscular disorder, as it supports optimal patient care, symptom management, and enhanced quality of life. For example, in July 2024, the American Medical Association, a U.S.-based professional association and lobbying group of physicians and medical students, reported that health spending in the United States rose by 4.1% in 2022, reaching $4.5 trillion, or $13,493 per capita. Therefore, increased healthcare spending is propelling the growth of the myasthenia gravis treatment market.

Product innovations are becoming a significant trend in the myasthenia gravis treatment market. Key companies in this sector are concentrating on developing new solutions to maintain their competitive edge. For example, in October 2023, UCB Pharma, a pharmaceutical company based in Belgium, announced that the US Food and Drug Administration (FDA) approved Zilucoplan for treating adults with generalized myasthenia gravis (gMG) who test positive for anti-acetylcholine receptor (AChR) antibodies. This approval adds a new treatment option for managing gMG, which is characterized by muscle weakness stemming from an autoimmune response. ZILBRYSQ stands out as a self-administered, once-daily subcutaneous complement C5 inhibitor, offering a convenient alternative to the traditional intravenous therapies that have long been the standard for treating gMG.

Major players in the myasthenia gravis treatment market are strategically embracing partnerships to usher in a patient-centric approach and redefine the delivery of care to rare disease populations. Strategic partnerships, characterized by the mutual leveraging of strengths and resources, have become a key avenue for collaboration. An illustrative example is the partnership between Huma Therapeutics, a UK-based digital health company, and UCB S.A., a Belgium-based biopharmaceutical company, announced in April 2023. This collaboration aims to introduce a digital health solution to enhance the management of the rare disease Myasthenia gravis (MG).

In November 2023, Selecta Biosciences, Inc., a biotechnology company based in the United States, announced its merger with Cartesian Therapeutics for an undisclosed amount. This merger enhances Selecta's dedication to RNA cell therapies for autoimmune diseases, particularly myasthenia gravis (MG). The partnership aims to leverage Cartesian's advanced RNA-engineering platform and pipeline, which includes the promising rCAR-T therapy Descartes-08, to accelerate development and provide effective treatment options. Cartesian Therapeutics is also a US-based biotechnology company focused on developing potential treatments for generalized myasthenia gravis.

Major companies operating in the myasthenia gravis treatment market include Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Baxter International Inc., Biogen Idec, Astellas Pharma Inc., CSL Limited, Chugai Pharmaceutical Co. Ltd., Grifols S.A, UCB Inc., Mitsubishi Tanabe Pharma Corp., Genentech Inc., Horizon Therapeutics plc, Amneal Pharmaceuticals Inc., Kedrion SpA, CuraVac Inc., AryoGen Pharmed, RemeGen Co. Ltd., Kashiv BioSciences LLC, Immunovant Inc., Cabaletta Bio Inc., Argenx SE, NMD Pharma A/S, Cartesian Therapeutics Inc., DAS Therapeutics Inc., Harbour BioMed Holdings Ltd., AnTolRx Inc., CytoDyn Inc., Ahead Therapeutics.

North America was the largest region in the myasthenia gravis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the myasthenia gravis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the myasthenia gravis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Myasthenia gravis treatment encompasses the provision of healthcare services by healthcare providers to address and manage myasthenia gravis, an autoimmune neuromuscular disease characterized by fatigue and weakness in the skeletal muscles.

The primary modalities for treating myasthenia gravis include medication, surgery, and other interventions. Medication involves the use of drugs to alleviate the symptoms associated with myasthenia gravis. One commonly prescribed medication is pyridostigmine, which facilitates the transmission of electrical signals between nerves and muscles. The treatment approach for myasthenia gravis incorporates various types of medications, such as cholinesterase inhibitors, corticosteroids, immunosuppressants, and others. These medications are administered in healthcare settings, including hospitals, clinics, and other healthcare facilities, to effectively manage the condition and improve the quality of life for patients.

The myasthenia gravis treatment market research report is one of a series of new reports that provides myasthenia gravis treatment market statistics, including myasthenia gravis treatment industry global market size, regional shares, competitors with a myasthenia gravis treatment market share, detailed myasthenia gravis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the myasthenia gravis treatment industry. This myasthenia gravis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The myasthenia gravis treatment market consists of sales of pyridostigmine, prednisone, azathioprine, and cyclosporine. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.